Advertisement
Canada markets open in 4 hours 47 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7332
    +0.0009 (+0.12%)
     

  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     

  • Bitcoin CAD

    87,827.91
    +751.59 (+0.86%)
     

  • CMC Crypto 200

    1,388.99
    -7.54 (-0.54%)
     

  • GOLD FUTURES

    2,359.40
    +16.90 (+0.72%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,758.25
    +190.75 (+1.09%)
     

  • VOLATILITY

    15.53
    +0.16 (+1.04%)
     

  • FTSE

    8,107.30
    +28.44 (+0.35%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6818
    -0.0003 (-0.04%)
     

SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit

SpringWorks Therapeutics, Inc.
·1 min read

STAMFORD, Conn., May 14, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on Friday, May 21st at 10:00AM ET.

To access the live webcast please visit the “Events & Presentations” page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the summit.

About SpringWorks Therapeutics

SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. SpringWorks has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with industry leaders to expand its portfolio. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

Contact:
Kim Diamond
Phone: 203-561-1646
Email: kdiamond@springworkstx.com